[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2000302678A - Hair activity by isoflavone derived from soybean - Google Patents

Hair activity by isoflavone derived from soybean

Info

Publication number
JP2000302678A
JP2000302678A JP11150382A JP15038299A JP2000302678A JP 2000302678 A JP2000302678 A JP 2000302678A JP 11150382 A JP11150382 A JP 11150382A JP 15038299 A JP15038299 A JP 15038299A JP 2000302678 A JP2000302678 A JP 2000302678A
Authority
JP
Japan
Prior art keywords
hair
male
estrogen
soybean
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11150382A
Other languages
Japanese (ja)
Inventor
Kaneyoshi Kubota
金嘉 窪田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KURESSENDO Corp KK
Original Assignee
KURESSENDO Corp KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KURESSENDO Corp KK filed Critical KURESSENDO Corp KK
Priority to JP11150382A priority Critical patent/JP2000302678A/en
Publication of JP2000302678A publication Critical patent/JP2000302678A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To solve a male depilation by keeping hormone balance in the body by administration of female hormone so as to adjust rise in reactivity of male hormone since the cause of male depilation is considered to be lessening of papilla and noncontinuation of the growth period in a hair period but not reduction in cell growth of hair-mother cells. SOLUTION: Isoflavone in a hypocotyl of soybean is considered to be a chemical substance to act as a phytoestrogen due to structural similarity to female hormone (estrogen). Daidzein and genistein are bonded to an estrogen receptor and show an estrogen action (agonist) and an antiestrogen action (antagonist) according to concentration. It is understood that 17β estradiol being a representative estrogen contains hydroxy groups at both ends and a flat ring structure common to isoflavonoid. A proper amount of isoflavone (phytoestrogen) derived from a hypocotyl of soybean structurally similar to the female hormone (estrogen) is orally administered so as to prevent and improve male depilation or white hair.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、毛髪に対する白髪
及び男性型脱毛の原因が、男性ホルモンと女性ホルモン
の体内バランスによるものと考え、男性ホルモンと女性
ホルモンとの体内バランス調整方法をどのようにすべき
か検索し、大豆由来のイソフラボンに注目した。このイ
ソフラボンの経口摂取により、体内のホルモンバランス
を調整して白髪及び男性型脱毛予防と活性に役立てるも
のです。
FIELD OF THE INVENTION The present invention is based on the assumption that the cause of gray hair and male pattern hair loss on hair is due to the internal balance of male and female hormones, and how to adjust the internal balance of male and female hormones. We searched for it and focused on isoflavones derived from soy. Oral ingestion of this isoflavone regulates hormonal balance in the body and helps prevent and activate gray hair and male pattern hair loss.

【0002】[0002]

【従来の技術】現在市販されている養毛・育毛剤の多く
は、血行を促進させる成分を主成分としています。最近
話題のミノキシジルも、そのような物質のひとつではな
いかと考えます。このようにほとんどが頭部に振りかけ
て毛髪活性させる製品のみで、体内のホルモンバランス
による経口摂取する養毛・育毛剤は販売されていませ
ん。
2. Description of the Related Art Most of the hair tonics and hair restorers currently on the market are mainly composed of components that promote blood circulation. I think minoxidil, which has recently been talked about, is one such substance. In this way, most products are only sprinkled on the head to activate the hair, and there are no hair growth and hair growth products that are taken orally due to hormonal balance in the body.

【0003】[0003]

【発明が解決しようとする課題】一般的な脱毛現象は、
男性型脱毛と円形脱毛症です。円形脱毛症や薬剤性の脱
毛症などでは、成長期の毛母細胞が何らかの理由で細胞
増殖を停止するために、毛幹の伸長が急速に止まり、休
止期毛に変化することによって脱毛します。これに対し
て男性型脱毛は、毛周期を重ねるにつれて毛の太さや長
さが減少していくものです。これは毛包が小さくなるた
めと、毛周期の成長期が短くなるためです。ですから、
脱毛というよりは薄毛化といったほうが実体に近いかも
しれません。
The general hair loss phenomenon is as follows.
Male pattern baldness and alopecia areata. In alopecia areata or drug-induced alopecia, the growth of the hair matrix stops cell growth for some reason, so the hair shaft elongates rapidly and loses hair by changing to telogen hair. . In contrast, male pattern hair loss reduces the thickness and length of hair as the hair cycle increases. This is due to the smaller hair follicles and the shorter anagen of the hair cycle. So,
Hair thinning may be closer to the body than hair loss.

【0004】男性型脱毛は年を重ねるにつれて進行する
もので、前髪の生え際から頭頂部にかけて薄毛化するの
が一般的です。男性型脱毛の進行に男性ホルモンが関与
している可能性については、アメリカのハミルトン医師
の研究があります。彼は、思春期またはそれ以前に去勢
された男性では、男性型脱毛が見られないことを発見し
ました。去勢によって睾丸を摘出すると、男性ホルモン
を作ることができなくなります。そこで、去勢された男
性に男性ホルモンを投与してみたところ、家系的に男性
型脱毛の素因のある男性に限って脱毛が見られるように
なりました。さらに、途中で投与を中止してもいったん
始まった脱毛症状は進行こそしないものの、元の状態に
戻ることはありませんでした。つまり、男性型脱毛は遺
伝的要因と男性ホルモンに依存し、不可逆的な変化であ
るということです。
[0004] Male pattern hair loss progresses with age, and it is common to thin the hair from the hairline of the bangs to the top of the head. A study by Dr. Hamilton in the United States has shown that male hormones may be involved in the progression of male pattern hair loss. He found no male pattern hair loss in men castrated or before castration. When the testicles are removed by castration, they can no longer make male hormones. Then, when male hormones were administered to castrated men, hair loss began to be seen only in men who were predisposed to male pattern hair loss in the family. Furthermore, even if the treatment was stopped halfway, alopecia symptoms that had begun once did not progress, but did not return to their original state. This means that male pattern hair loss is an irreversible change that depends on genetic factors and male hormones.

【0005】毛の発達と男性ホルモンの関係は、男性は
思春期に睾丸が発達し、男性ホルモンを盛んに作りはじ
めます。この男性ホルモンの働きによって、髭、胸毛、
すね毛など男性に特徴的な毛が発達するのです。ちなみ
に思春期には男女ともわき毛と陰毛が発達しますが、こ
れらの毛の発育にも男性ホルモンが関係しています。男
性ホルモンは、その受容体である男性ホルモンリセプタ
ーと結合して、さまざまな遺伝子の発現を調節します。
男性ホルモンリセプターが欠失している睾丸性女性化症
の患者では、髭や胸毛のほか、わき毛や陰毛も発達しま
せん。つまり男性ホルモンの情報が正常に伝わらない
と、これらの毛を発達させる遺伝子プログラムがうまく
動かなくなります。血中の男性ホルモンの濃度は男性型
脱毛の男性とそうでない男性との間で違いはありませ
ん。男性ホルモンが多いために薄毛化が進むのではな
く、遺伝的な要因などによって男性ホルモンに対する感
受性、或は男性ホルモンを受け取った後の遺伝子プログ
ラムに個人差があるために、男性ホルモンの血中濃度が
同じでも男性型脱毛が起きたり起きなかったりするので
す。頭髪では前頭部の毛包と後頭部の毛包との間で、男
性ホルモンリセプターの量と5αリダクターゼはパピラ
細胞に比較的多く存在しますが、毛母細胞にはほとんど
ありません。したがって、男性ホルモンは毛母細胞に直
接はたらいて毛の伸長速度や毛周期の長さを変えている
のではなく、まずパピラに取り込まれて何らかの変化を
ひきおこし、その結果、毛母細胞に作用するようです。
男性ホルモンがパピラ細胞の増殖因子の分泌などを変化
させることによって、頭髪の薄毛化をひきおこしている
と推測されます。また、皮脂を分泌する皮脂腺も男性ホ
ルモンによって発達します。毛包も皮脂腺も年齢を重ね
るにつれて、男性ホルモンに対する反応性が非常に高ま
ることにより、男性ホルモンの濃度が上昇する思春期で
はなく、もっと年をとってから、これらの変化(男性型
脱毛や白髪)が現われるものと思われます。それでは、
男性ホルモンの作用を止めれば、男性型脱毛は防げるの
か。原理的にはその通りですが、男性ホルモンは男性特
有の機能の発達や維持に深く関与していますので、副作
用が問題になります。
[0005] The relationship between hair development and male hormones is that males develop testicles during puberty and begin to make male hormones actively. By the action of this male hormone, beard, chest hair,
Hair characteristic of men, such as shin hair, develops. By the way, men and women develop side hair and pubic hair during puberty, and male hormones are also involved in the growth of these hairs. Androgens regulate the expression of various genes by binding to their receptors, the androgen receptors.
Patients with testicular feminization who lack the androgen receptor do not develop beards, chest hairs, or side and pubic hair. In other words, if the information on male hormones is not transmitted properly, the genetic programs that develop these hairs will not work properly. The levels of androgens in the blood do not differ between men with androgenetic alopecia and those who do not. The concentration of male hormones in the blood is not due to the increase in hair thinning due to the large number of male hormones, but due to individual differences in the sensitivity to male hormones due to genetic factors or the genetic program after receiving male hormones. Even if they are the same, male pattern hair loss may or may not occur. In the scalp hair, between the forehead and occipital hair follicles, the amount of androgen receptor and 5α-reductase are relatively high in papilla cells, but scarcely in hair mother cells. Therefore, androgens do not act directly on hair cells to alter the rate of hair growth or the length of the hair cycle, but are first taken up by papillae and cause some changes, which in turn act on hair cells. It seems that.
It is presumed that male hormones cause hair thinning by altering the secretion of growth factors of papilla cells. Sebaceous glands that secrete sebum are also developed by male hormones. As the hair follicles and sebaceous glands age, they become much more responsive to androgens, and the levels of androgens rise, rather than puberty, when these changes (male hair loss or gray hair) ) Will appear. Then,
Does stopping male hormones prevent male pattern hair loss? As a matter of principle, male hormones are deeply involved in the development and maintenance of male-specific functions, so side effects are a problem.

【0006】また、女性特有の現象として、赤ちゃんを
産んだ後3〜4ケ月して髪の毛が抜けることがありま
す。これは分娩後脱毛症といって、女性ホルモンの影響
によるものです。女性ホルモンには毛周期を延長させる
働きがあります。妊娠中には持続的に女性ホルモンが分
泌されるため、本来であれば毛周期を終えて休止期に入
るはずの毛包も成長期にとどめられることになります。
出産後に女性ホルモンのレベルが下がると、これらの毛
包がいっせいに休止期に入るため、一時に大量の毛が抜
けることになるのです。男性型脱毛は、毛母細胞の細胞
増殖低下ではなく、パピラが小さくなることと毛周期の
成長期が持続しないことが原因であると考えられていま
すから、男性ホルモンの反応性の高まりを調整するため
に、毛周期を延長させる働きがある女性ホルモンを投与
することにより体内のホルモンバランスを保ち、男性型
脱毛を解決することが課題であります。
Also, as a phenomenon peculiar to women, hair may come off three to four months after giving birth to a baby. This is called postpartum alopecia and is due to the effects of female hormones. Female hormones work to prolong the hair cycle. Since female hormones are continuously secreted during pregnancy, hair follicles that would otherwise end the hair cycle and enter into a telogen are also kept in anagen.
When female hormone levels drop after giving birth, these hair follicles go into a telogen, causing a large amount of hair to fall off at one time. It is thought that male pattern hair loss is not due to a decrease in cell proliferation of hair matrix cells, but to a decrease in papillae and a lack of sustained anagen during the hair cycle. In order to achieve this, the challenge is to maintain female hormonal balance by administering female hormones that work to prolong the hair cycle, and to resolve male pattern hair loss.

【0007】[0007]

【課題を解決するための手段】本発明は、女性ホルモン
の経口投与による男性型脱毛及び白髪に対する毛髪活性
ですが、女性ホルモンは一般的な店舗では販売されてい
ませんから、入手するのが困難です。そこで、着目した
のが大豆の胚軸由来のイソフラボンです。イソフラボン
は、女性ホルモン(エストロゲン)の減少による女性の
更年期障害や骨粗しょう症の予防と治療に利用され、効
果が証明されています。イソフラボンは女性ホルモン
(エストロゲン)との構造類似性から大豆中のフィトエ
ストロゲンとして働く化学物質と考えられています。d
aidzein、genisteinはエストロゲンレ
セプターへ結合し、濃度に応じてエストロゲン作用(ア
ゴニスト)や抗エストロゲン作用(アンタゴニスト)を
示します。代表的なエストロゲンである17βエストラ
ジオールがイソフラボノイドに両端の水酸基と平板な環
状構造が共通していることがわかります。この女性ホル
モン(エストロゲン)と構造的に類似している大豆の胚
軸由来のイソフラボン(フィトエストロゲン)を、男性
型脱毛或は白髪に対する毛髪活性を目的として、適量を
経口摂取することです。
[Means for Solving the Problems] The present invention relates to hair activity against male pattern hair loss and gray hair by oral administration of female hormones, but it is difficult to obtain female hormones because they are not sold in general stores. is. We focused on isoflavones derived from the hypocotyl of soybeans. Isoflavones have been shown to be effective in preventing and treating menopause and osteoporosis in women due to a decrease in female hormones (estrogens). Isoflavones are thought to be chemicals that act as phytoestrogens in soybeans due to their structural similarity to the female hormone (estrogens). d
Aidzein and genistin bind to estrogen receptor and show estrogen action (agonist) or anti-estrogen action (antagonist) depending on the concentration. It can be seen that 17β estradiol, a typical estrogen, has the same hydroxyl group at both ends and a flat cyclic structure as isoflavonoids. The isoflavone (phytoestrogen) derived from the hypocotyl of soybean, which is structurally similar to this female hormone (estrogen), is taken orally in an appropriate amount for the purpose of male pattern hair loss or hair activity against gray hair.

【0008】[0008]

【発明の実施の形態】本発明の大豆の胚軸由来のイソフ
ラボンは、フィトエストロゲンを有効成分とする大豆食
品を、自体公知の食品あるいは食品成分、医薬担体また
は賦形剤と自体公知の方法で合して、毛髪を活性させる
食品とすることができます。用いる食品あるいは食品成
分は特に限定するものではなく、目的とする毛髪活性及
び脱毛予防の具体的用途に応じて当業者が適宜選択でき
ます。また、毛髪活性及び脱毛予防の形態も特に限定す
るものではなく、具体的用途に応じて、種々の個体や形
状にすることができます。本発明の毛髪活性及び脱毛予
防の効果を発揮させるために、特に重要なことは、大豆
の胚軸由来のイソフラボンの配合率で、一日の摂取量を
厳守して製品化することが大切です。体内摂取の方法
は、経口摂取によります。フィトエストロゲンを有効成
分とする大豆の胚軸由来のイソフラボンを経口摂取する
場合、成人に対して1日あたり、有効成分として40m
g〜200mg程度として、これを1日1〜数回に分け
て摂取することにより、副作用なく所望の効果を発揮さ
せることができます。
BEST MODE FOR CARRYING OUT THE INVENTION The isoflavone derived from the hypocotyl of soybean of the present invention can be prepared by converting a soybean food containing phytoestrogens as an active ingredient into a foodstuff known per se or a food ingredient, a pharmaceutical carrier or an excipient by a method known per se. Together, it can be a food that activates hair. The food or food ingredient to be used is not particularly limited, and can be appropriately selected by those skilled in the art according to the intended use of hair activity and the specific use of hair loss prevention. In addition, the form of hair activity and hair loss prevention is not particularly limited, and can be made into various individuals and shapes depending on the specific application. In order to exert the effect of the present invention on the hair activity and the prevention of hair loss, it is particularly important to commercialize the soybean hypocotyl derived isoflavones from the blending ratio of daily soybeans. . The method of ingestion depends on oral intake. When orally ingesting isoflavones derived from soy hypocotyls containing phytoestrogens as an active ingredient, 40 m / day as an active ingredient for adults
By taking this in the form of g-200mg, divided into one or several times a day, the desired effect can be achieved without side effects.

【0009】[0009]

【実施例】本発明の大豆の胚軸由来のイソフラボンを、
10粒中で100mg配合して製品化を試みました。形
状は打錠品のタブレットとした。他の食品成分として、
ゴマミネラル、アミノ酸を配合した。このようにして製
品化された男性型脱毛活性剤を、23才のデ杯選手のテ
ニスプレヤーに経口摂取することを依頼して、毎日10
粒程度を摂取した。野外での試合や練習により、汗をか
いて帽子を被っているため、頭髪の状態はいつも最悪で
前頭部の毛髪が薄毛化していた。4ケ月飲み続けた結
果、前頭部に産毛が見えはじめた。
EXAMPLE The isoflavone derived from the hypocotyl of soybean of the present invention was
We tried to commercialize it by blending 100mg in 10 tablets. The shape was a tablet tablet. As other food ingredients,
Sesame mineral and amino acid were blended. The male-type hair removal activator commercialized in this way was asked to take orally by a tennis player of a 23-year-old decup player,
I took about a grain. His hair condition was always the worst, and his frontal hair was thinning, because he was sweating and wearing a hat during an outdoor game or practice. As a result of continuing to drink for 4 months, hair growth began to appear on the frontal region.

【0010】[0010]

【発明の効果】現在の研究では、主に髭の発達や男性型
脱毛にかかわっているII型5αリダクターゼの活性を
阻害する薬剤が進められています。その研究は、毛髪活
性が男性ホルモンと女性ホルモンとの関係によるものと
思われます。たとえば、前立腺癌の治療に女性ホルモン
が投与されていますが、当初エストロゲン作用によると
考えられていたのですが、男性ホルモンのテストステロ
ンをつくる5αリダクターゼ還元酵素を阻害すること、
さらにフリーラジカルである過酸化脂質の低下などの多
様な作用が複合して効いている可能性が高いことが検証
されました。その患者の多くに毛髪活性の現象が起きて
いることです。また、女性特有の現象として、赤ちゃん
を産んだ後3〜4ケ月して髪の毛が抜けることがありま
す。これは分娩後脱毛症といって、女性ホルモンの影響
によるものです。女性ホルモンには毛周期を延長させる
働きがあります。妊娠中には持続的に女性ホルモンが分
泌されるため、本来であれば毛周期を終えて休止期に入
るはずの毛包も成長期にとどめられることになります。
出産後に女性ホルモンのレベルが下がると、これらの毛
包がいっせいに休止期に入るため、一時に大量の毛が抜
けることになるのです。大豆の胚軸由来のイソフラボン
の経口摂取は、女性ホルモン(エストロゲン)との構造
類似性からフィトエストロゲンとして働く化学物質と考
えられ、男性型脱毛などに効果が期待されます。
[Effects of the Invention] In the current research, drugs that inhibit the activity of type II 5α reductase, which is mainly involved in beard development and male pattern hair loss, are being advanced. The study suggests that hair activity is due to the relationship between male and female hormones. For example, female hormones are used to treat prostate cancer, and it was originally thought to be due to estrogenic effects. Inhibiting 5α reductase reductase, which produces the male hormone testosterone,
Furthermore, it was verified that various actions such as reduction of free radical lipid peroxide are likely to be effective in combination. Many of those patients have hair activity phenomena. Also, as a phenomenon peculiar to women, hair may fall out three to four months after giving birth to a baby. This is called postpartum alopecia and is due to the effects of female hormones. Female hormones work to prolong the hair cycle. Since female hormones are continuously secreted during pregnancy, hair follicles that would otherwise end the hair cycle and enter into a telogen are also kept in anagen.
When female hormone levels drop after giving birth, these hair follicles go into a telogen, causing a large amount of hair to fall off at one time. Oral ingestion of isoflavones from soybean hypocotyls is considered to be a chemical substance that acts as a phytoestrogen due to its structural similarity to the female hormone (estrogen), and is expected to be effective in male pattern hair loss.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】大豆由来のイソフラボンを経口摂取するこ
とによる毛髪活性。
1. Hair activity by oral ingestion of isoflavones derived from soybean.
JP11150382A 1999-04-21 1999-04-21 Hair activity by isoflavone derived from soybean Pending JP2000302678A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11150382A JP2000302678A (en) 1999-04-21 1999-04-21 Hair activity by isoflavone derived from soybean

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11150382A JP2000302678A (en) 1999-04-21 1999-04-21 Hair activity by isoflavone derived from soybean

Publications (1)

Publication Number Publication Date
JP2000302678A true JP2000302678A (en) 2000-10-31

Family

ID=15495785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11150382A Pending JP2000302678A (en) 1999-04-21 1999-04-21 Hair activity by isoflavone derived from soybean

Country Status (1)

Country Link
JP (1) JP2000302678A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000302667A (en) * 1999-04-23 2000-10-31 Kobe Tennenbutsu Kagaku Kk Accelerator for ample breasts
EP1074240A3 (en) * 1999-07-27 2003-01-29 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
WO2004019962A1 (en) * 2002-08-28 2004-03-11 Sunstar Inc. Hair growth stimulants for oral use
JP2004182600A (en) * 2001-10-31 2004-07-02 Daicho Kikaku:Kk Preparation for skin
KR100500641B1 (en) * 2002-07-25 2005-07-12 주식회사 태평양 Composition for preventing falling out of the hair or promoting growth of the hair containing isoflavone aglycon genistein
EP1841397A1 (en) * 2004-12-24 2007-10-10 Dolphst Pty Ltd Formulations and treatments for trichology
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
JP2012193200A (en) * 2001-10-31 2012-10-11 Daicho Kikaku:Kk Dermatologic preparation
CN102935140A (en) * 2012-11-20 2013-02-20 云爱华 Traditional Chinese medicine for treating white hairs
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
KR101286152B1 (en) 2010-12-17 2013-07-15 계명대학교 산학협력단 Composition for Improving Vitiligo or Canities Comprising Extract from Glycine maxim As Active Ingredient
CN103417647A (en) * 2013-08-22 2013-12-04 纪雪娥 Liquid traditional Chinese medicine capable of blackening white hair and having hair growth function and preparation method thereof
WO2021256233A1 (en) * 2020-06-15 2021-12-23 国立大学法人東海国立大学機構 Hair graying inhibitor

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
JP2000302667A (en) * 1999-04-23 2000-10-31 Kobe Tennenbutsu Kagaku Kk Accelerator for ample breasts
EP1074240A3 (en) * 1999-07-27 2003-01-29 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
JP2012193200A (en) * 2001-10-31 2012-10-11 Daicho Kikaku:Kk Dermatologic preparation
JP2004182600A (en) * 2001-10-31 2004-07-02 Daicho Kikaku:Kk Preparation for skin
JP2014208697A (en) * 2001-10-31 2014-11-06 有限会社大長企画 Agent for the skin of animals
KR100500641B1 (en) * 2002-07-25 2005-07-12 주식회사 태평양 Composition for preventing falling out of the hair or promoting growth of the hair containing isoflavone aglycon genistein
WO2004019962A1 (en) * 2002-08-28 2004-03-11 Sunstar Inc. Hair growth stimulants for oral use
EP1841397A1 (en) * 2004-12-24 2007-10-10 Dolphst Pty Ltd Formulations and treatments for trichology
EP2481389A1 (en) * 2004-12-24 2012-08-01 Dolphst Pty Ltd Formulations and treatments for trichology
US8440239B2 (en) 2004-12-24 2013-05-14 Dolphst Pty Ltd. Formulations and treatments for trichology
EP1841397A4 (en) * 2004-12-24 2010-01-27 Dolphst Pty Ltd Formulations and treatments for trichology
KR101286152B1 (en) 2010-12-17 2013-07-15 계명대학교 산학협력단 Composition for Improving Vitiligo or Canities Comprising Extract from Glycine maxim As Active Ingredient
CN102935140A (en) * 2012-11-20 2013-02-20 云爱华 Traditional Chinese medicine for treating white hairs
CN103417647A (en) * 2013-08-22 2013-12-04 纪雪娥 Liquid traditional Chinese medicine capable of blackening white hair and having hair growth function and preparation method thereof
WO2021256233A1 (en) * 2020-06-15 2021-12-23 国立大学法人東海国立大学機構 Hair graying inhibitor

Similar Documents

Publication Publication Date Title
JP2000302678A (en) Hair activity by isoflavone derived from soybean
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US8440239B2 (en) Formulations and treatments for trichology
EP1023889B1 (en) A hair lotion for preventing hair loss comprising extracts of hop, rosemary and Swertia, further containing silanodiol salicylate
US8985124B2 (en) Method for treatment of hair loss with a combination of natural ingredients
WO2001030311A1 (en) Agent for inducing hair growth containing extracts of saw palmetto and swertia
US20040213859A1 (en) Organic nutrient for hair loss treatment
JP2000038340A (en) Hair grower and food
MX2007007731A (en) Formula ions and treatments for well-being.
WO2002011675A2 (en) Organic nutrient for hair loss treatment
KR20030036536A (en) composite that have improvement effect vitality of scalp and hair
SCHRIOCK et al. Treatment of hirsutism
JPH11269043A (en) Cosmetic for scalp and hair
EP3511006B1 (en) Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient
AU771256B2 (en) Medicaments comprising relaxin and their use
US20240189201A1 (en) Hair serum and supplement
US20080233213A1 (en) Hair sustaining formulation
Behrman Diagnosis and management of hirsutism
EP3668482B1 (en) Combination therapy for hair loss
Wiseman et al. Therapeutic approach to androgenetic alopecia
JP2001103931A (en) Food composition
Goudar et al. Evaluation of choice of medicine for hair growth in practising hair implant surgeons-original research
Piérard-Franchimont et al. Androgenic alopecia
Jannat et al. Common Treatment Formulation for Non-Scaring (Androgenetic) Alopecia
Chidrawar et al. TRACTION ALOPECIA: A REVIEW